Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT06787053

Selecting Hypoxic Tumours for Treatment Modification

Selecting Hypoxic Tumours for Treatment Modification — Recruiting • Oncology • NCT06787053.

📅 12 May 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06787053
Sponsor
University of Manchester
Start
2024-10-16
ClinicaliQ Trial Snapshot
  • Selecting Hypoxic Tumours for Treatment Modification — Recruiting • Oncology • NCT06787053.
  • What is being tested: Methods to identify and select patients with hypoxic solid tumours for treatment intensification strategies, since hypoxic tumours demonstrate reduced radiotherapy responsiveness compared to normoxic tumours.
  • Patient eligibility overview: Solid tumour patients scheduled for radiotherapy, with particular focus on the >25% of this population with hypoxic tumours, who currently have poor treatment outcomes with standard radiotherapy alone.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Approximately 50% of cancer patients with solid tumours will be treated with radiotherapy. A significant proportion (>25%) of patients have hypoxic tumours which respond poorly to radiotherapy. Hypoxic tumours have a poor prognosis. This can be improved with treatment intensification. Treatment intensification can be modification with CON (breathing O2-enriched air + oral administration of nicotinamide), chemoradiosensitisation, radiation dose-escalation or additional systemic treatments, significantly improving response of the tumours to radiotherapy. However, there are currently no clinically approved biomarkers to identify hypoxic tumours. Our group has developed and validated gene-expression signature-based…

Eligibility Snapshot
  • : This will be tumour site dependent. Bladder: * Older than age 18 years. * Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner. * Able to give informed consent. Cervix: * Older than age 18 years. * Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner. * Able to give informed consent. Prostate: * Older than age 18 years. * Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner. * Able to give informed consent.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer
Oncology · 14 Jul 2026
Pembrolizumab combined with chemoradiotherapy is recommended for untreated locally advanced cervical cancer, improving survival outcomes compared to chemoradiotherapy alone—consider this combination as…
View guideline →
Guideline
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
Oncology · 16 Jun 2026
First-line treatment option: Cemiplimab combined with platinum-based chemotherapy is recommended by NICE for patients with untreated advanced non-small-cell lung cancer (NSCLC), offering…
View guideline →
Guideline
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)
Oncology · 16 Jul 2026
Evaluation terminated – NICE discontinued appraisal of lutetium-177 vipivotide tetraxetan; this agent is not recommended for routine NHS use and should not…
View guideline →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Guideline
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Oncology · 09 Jul 2026
Cemiplimab is recommended as a treatment option for patients with recurrent or metastatic cervical cancer only after progression on or following platinum-based…
View guideline →